Pulmonary arterial hypertension (PAH) is a severe disease with high mortality[@b1][@b2][@b3]. Till now some prognostic factors, including clinical signs of right heart failure, impaired exercise capacity, right ventricular dysfunction and impaired pulmonary hemodynamics have been associated with poor outcome[@b1][@b2][@b3]. Recently, more focus has been placed on the prognostic role of alterations in the glucose and lipid metabolism[@b4][@b5][@b6][@b7]. Low high-density lipoprotein cholesterol (HDL-C) in PAH patients has been associated with worse clinical outcomes and higher mortality. This finding was independent of cardiovascular risk factors, insulin resistance and severity of the disease. It was hypothesized that anti-inflammatory properties of HDL-C, its ability to enhance prostacyclin half-life and its protective role in endothelium could explain its impact on prognosis in PAH[@b4][@b5][@b6][@b7].

Low-density lipoprotein cholesterol (LDL-C) is an established marker of cardiovascular risk[@b8]. While high LDL-C levels are associated with worse prognosis in the general population, there are some populations with chronic diseases including diabetes, heart failure[@b9], chronic kidney disease[@b10][@b11] and rheumatoid arthritis[@b12][@b13] where low LDL-C levels have been linked to increased mortality.

In PAH, low LDL-C levels might accelerate disease progression by several mechanisms including exacerbation of inflammation[@b14][@b15] and direct effects on the arterial wall[@b16]. In fact, we have recently shown that low LDL-C levels are associated with increased stiffness of pulmonary arteries[@b16]. Conversely, as observed in other diseases, chronic inflammation[@b14][@b15], hepatic congestion[@b17] and low nutritional status[@b18][@b19] might be associated with reduced LDL-C levels in individuals with PAH. If this is true, clinical improvement of a patient could lead to normalization of LDL-C levels. However, data regarding the role of LDL-C in PAH is scarce.

We therefore investigated whether LDL-C levels are altered in PAH patients and whether they are associated with survival in this group. Additionally, we evaluated whether reversal of pulmonary hypertension (PH) can influence LDL-C levels. For this purpose we studied another group of patients with chronic thromboembolic pulmonary hypertension (CTEPH) which is the only potentially curable type of PH.

Results
=======

PAH population
--------------

The PAH sample included 140 patients. The majority (n = 109; 78%) of them were newly diagnosed and treatment naive at inclusion. The remaining patients were already on monotherapy with sildenafil (n = 14; 10%), endothelin receptor antagonists (n = 13; 9.3%), or prostanoids (n = 2; 1.4%) or on combination therapy with endothelin receptor antagonists and sildenafil (n = 2, 1.4%). At enrollment 15 patients used atorvastatin at mean dose of 20.7 ± 8.8 mg and 13 patients used simvastatin at mean dose of 17.9 ± 4.3 mg. During the observation period the doses did not changed significantly, respectively 18.7 ± 11.3 mg for atorvastatin (p = 0.59) and 15.4 ± 12.3 mg (p = 0.5) for simvastatin. Diabetes was present in 11 (7.8%) patients, hypertension in 35 (25%) patients, obesity in 18 (13%) patients and overweight in 38 (27%) patients. Eight (5.7%) patients were active smokers, no patient declared alcohol abuse. The mean creatinine level was 85.9 ± 42.9 μmol/l, mean aspartate transaminase (AST) 28.4 ± 12.8 U/l, and mean alanine transaminase (ALT) 29.7 ± 29.9 U/l. Seventeen (12%) patients were actively treated due to thyroid function abnormalities, however at enrollment all patients had thyroid stimulating hormone (TSH) values within normal range. Twenty two (16%) patients had higher education and 38 (27%) patients were still working full-time at enrollment. As most (n = 99; 70.7%) patients were in World Health Organization functional class (WHO-FC) III their daily activities were limited. The patients were not advised any specific dietary recommendations. Clinical, demographic, laboratory and hemodynamic data of PAH population are presented in [Table 1](#t1){ref-type="table"}.

Comparison with age and sex-matched controls
--------------------------------------------

LDL-C was stable during 3 month follow-up: 2.57 ± 0.88 mmol/l at enrollment and 2.59 ± 0.98 mmol/l at follow-up; p = 0.67. As compared to controls it was lower in PAH women, men and patients who did not use statins ([Table 2](#t2){ref-type="table"}). LDL-C levels were similar in the subgroups of idiopathic PAH (IPAH), PAH associated with connective tissue disease (CTD-PAH), and PAH associated with congenital heart disease (CHD-PAH) (2.4\[1.7--3.0\] vs 2.8 \[2.1--3.6\] vs and 2.6 \[2.1--3.0\] mmol/l, respectively, p = 0.83). Sex--specific comparisons of other cardiovascular risk factors between PAH patients and age-matched controls are presented in [Table 2](#t2){ref-type="table"}.

Clinical characteristics and LDL-C levels
-----------------------------------------

The associations of age, sex, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, cardiovascular risk factors, markers of PAH severity and LDL-C levels are presented in [Table 3](#t3){ref-type="table"}. In univariate linear regression analysis triglycerides (TG), WHO-FC class and sex were associated with LDL-C level, however in a multiple regression model \[R^2^ = 0.26, F(2, 86) = 15.2, p \< 0.001\] including all variables given in [Table 3](#t3){ref-type="table"} significant relationship with LDL-C remained only for TG (beta coefficient \[standard error\] = 0.46 \[0.09\], p \< 0.001) and WHO-FC (β coefficient \[standard error\] = −0.27 \[0.09\], p = 0.005). In a subgroup of 108 patients in whom high-sensitivity C-reactive protein (hsCRP) was available (patients recruited after January 2011) we found a significant correlation (r = −0.24 and p = 0.01) between this marker and LDL-C level.

LDL-C for the prediction of death in PAH
----------------------------------------

In the PAH sample, 32 patients died after a median follow-up time of 33[@b20] months. Spline analysis revealed the association between LDL-C levels and survival to be linear ([Fig. 1](#f1){ref-type="fig"}), allowing to model LDL-C in this way. Lower LDL-C levels were significantly associated with all-cause mortality in univariable analysis (HR: 0.44 per 1 mmol/l, 95% CI: 0.26--0.74, p = 0.002, [Table 4](#t4){ref-type="table"}) and after hierarchical adjustment for risk factors (HR in fully-adjusted model: 0.18 per 1 mmol/l, 95% CI: 0.07--0.47, p \< 0.001, [Table 4](#t4){ref-type="table"}). Similar results were found when only patients who did not use statins were analysed (HR in fully-adjusted model: HR = 0.19 per mmol/l, 95% CI = 0.06--0.46, p \< 0.001).

LDL-C changes after treatment in CTEPH patients
-----------------------------------------------

The total CTEPH population in our registry consisted of 34 patients (14 males) aged 64.5 \[52.0--71.0\] years. They were in WHO FC II (n = 4), III (n = 28), and IV (n = 2) on presentation. Similar to the PAH group, the CTEPH patients had lower LDL-C levels than the age and sex-matched control patients from the NATPOL study (2.7 ± 0.7 mmol/l vs. 3.2 ± 1.1 mmol/l, p \< 0.001). In 21 patients we had data on LDL-C and hemodynamics at baseline and follow-up. The reversed CTEPH (rCTEPH) group consisted of 11 patients (4 males) aged 47.0 \[42.0--65.0\] years, in whom by definition mPAP decreased at least by ≥10 mmHg and to \<30 mmHg. In this group mPAP decreased from 40\[31--50\] to 23\[19--27\] mmHg; p = 0.015, pulmonary vascular resistance (PVR) from 8.7\[2.5--11.5\] to 2.6\[2.1--5.3\] WU, p = 0.015, right atrial pressure (RAP) from 6.5 \[4--9\] to 5\[2--14\] mmHg; p = 0.1, while cardiac index (CI) increased from 2.1 \[1.7--2.5\] to 2.5 \[2.0--2.7\]; p = 0.045. The nonreversed (nrCTEPH) group consisted of 10 patients (5 males) aged 66.0 \[61.0--77.0\] years in whom by definition there was no significant decrease of mPAP during observation. In this group hemodynamic parameters were similar at baseline and at follow-up (mPAP 50.5\[46--56\] vs 47\[43--51\] mmHg; p = 0.85, PVR 13.5\[13.0--14.7\] vs 13.1 \[10.7--13.7\] WU; p = 0.80, RAP 3\[1--4\] vs 5\[2--14\] mmHg; p = 1.0, CI 1.8\[1.7--1.9\] vs 1.9\[1.7--2.3\] l/min/m^2^; p = 1.0).

rCTEPH patients were treated with pulmonary endarterectomy (PEA, n = 4) or balloon pulmonary angioplasty (BPA, 5.0 \[2.0--7.0\] sessions per patient; n = 7) while nrCTEPH patients had monotherapy with riociguat (n = 1), sildenafil (n = 2), subcutaneous treprostinil (n = 1), one BPA session (n = 3), or a combination of sildenafil and subcutaneous treprostinil (n = 2) or subcutaneous treprostinil and one BPA session (n = 1). Follow-up time was similar in the rCTEPH and nrCTEPH group (12 \[7--30\] vs 18 \[11--25\] months, p = 0.5). During this time LDL-C increased from 2.6 \[2.1--3.2\] to 4.0 \[2.8--4.9\] mmol/l; p = 0.045 in the rCTEPH group, but remained unchanged in nrCTEPH patients: 2.4 mmol/l \[2.2--2.7\] vs 2.3 mmol/l \[2.1--2.5\], p = 1.0 ([Fig. 2](#f2){ref-type="fig"}).

Discussion
==========

In the present study we show that PAH patients have decreased LDL-C levels, and that low LDL-C levels are associated with increased risk of all-cause mortality. Furthermore, we demonstrate that in CTEPH patients significant improvement of hemodynamic parameters is associated with reversal of decreased LDL-C levels.

Metabolic changes as reflected by decreased levels of HDL-C and increased insulin resistance have been described previously in the PAH population[@b4][@b5][@b6][@b7]. Low HDL-C in PAH patients has been associated with worse clinical outcomes and higher mortality. This finding was independent from cardiovascular risk factors, insulin resistance and severity of the disease. This phenomenon may be explained by antiinflammatory properties of HDL-C, its ability to enhance prostacyclin half-life and its protective role in endothelial dysfunction.

The phenomenon of reduced LDL-C levels has already been described in other chronic diseases such as rheumatoid arthritis[@b12], cancer[@b20], end-stage renal failure[@b11] or chronic heart failure[@b21] however, to the best of our knowledge this is the first study reporting changes in LDL-C levels and their prognostic role in PAH patients. Potential explanations for these findings include a chronic inflammatory state[@b22], malnutrition[@b18], and altered liver metabolism[@b17].

Inflammatory cytokines are able to activate the reticuloendothelial system leading to enhanced receptor-independent clearance of LDL-C[@b23]. Conversely, suppression of the reticuloendothelial system leads to inhibition of LDL-C clearance[@b24]. Studies in rheumatoid arthritis have shown that suppression of inflammation with disease-modifying antirheumatic drugs or biological agents which target specific proinflammatory cytokines was accompanied by an increase in total cholesterol and LDL-C levels[@b25][@b25]. What is more, this increase was able to differentiate responders from non-responders to antirheumatic therapies[@b27]. An expanding body of knowledge suggests that inflammation and altered immune processes underlie both development and progression of PAH[@b14][@b28]. In fact we found a significant correlation between hsCRP and LDL-C in subgroup analysis of our PAH patients. However further studies are needed to fully understand the relationship between inflammation and lipid profile in this group.

As the liver plays a central role in lipid metabolism controlling both production and clearance of serum lipoproteins it seems likely that its dysfunction could contribute to altered LDL-C levels in PAH. Right heart dysfunction can lead to congestive hepatopathy, which is related to right atrial pressure and the degree of tricuspid regurgitation[@b17]. In fact, in our study we demonstrated that significant improvement of pulmonary hemodynamics in CTEPH patients was associated with normalization of LDL-C plasma levels. However, the exact pathophysiological pathways involved still need to be identified, since LDL-C normalization might not only be a direct consequence of hemodynamic improvement but also may result from improvement of the general condition of the patient[@b29][@b30].

Low LDL-C levels have also been found in malnourished patients with chronic heart failure[@b9]. Accordingly, malnutrition could also contribute to the observed reduction of LDL-C in PAH patients. However, in our cohort none of the available markers of malnutrition such as body mass index (BMI) were associated with LDL-C level.

Several concomitant disorders and lifestyle interventions can influence LDL-C level[@b31]. Dietary changes, reduction of excessive body weight and increase in habitual physical activity may lead to lowering LDL-C concentration[@b32]. However we do not think that these lifestyle factors had significant impact on LDL-C level in our population. First, no specific recommendations on dietary patterns or weight reduction has been given to patients due to lack of scientific evidence. Second, the ability to increase of physical activity is limited in PAH patients due to exertional dyspnea. Third, most of our patients were within reference values for BMI and we did not find any correlation between LDL-C and BMI. Renal or hepatic impairment as well as thyroid abnormalities can also influence LDL-C level. In our patients, however, we did not find any associations between markers of these disorders (ALT, AST, creatinine) and LDL-C level. Thyroid abnormalities when present were well controlled. An important modulator of LDL-C concentration is the use of statins. Therefore, when we compared LDL-C levels to controls we analyzed separately all PAH patients and PAH patients who did not use statins. In both comparisons LDL-C levels were significantly decreased in PAH group. We monitored the use of statins at follow-up and did not find significant change in the number of patients who used these drugs as well as doses of statins in individual patients. In multivariable analysis we considered the use of statins as a potential confounder.

Our study suggests that traditional interpretation of hypercholesterolemia as a risk factor for increased mortality may not apply in PAH population. Instead, our finding of the deleterious signal of low LDL-C levels in PAH corresponds with the concept of cholesterol paradox and reverse epidemiology whereby lower levels of traditional risk factors are associated with worse prognosis[@b22]. The evidence of a survival advantage associated with higher cholesterol levels has been provided for several populations with debilitating disorders such as heart failure[@b9], rheumatoid arthritis[@b12], acute myocardial infarction[@b33][@b34] and in the elderly[@b35][@b36].

The mechanism of interaction between LDL-C and clinical outcome has not been investigated in PAH. In other populations the importance of lipoproteins in down-regulation of the inflammatory immune response[@b9] and prevention of malnutrition[@b18] has been claimed. Lipids and lipoproteins can modulate inflammatory markers[@b22][@b37][@b38][@b39][@b40]. Cholesterol can bind and neutralize endotoxin and liposaccharide components of infectious agents, thereby down-regulating the inflammatory state, which has been linked to progression of PAH[@b14][@b28][@b41]. Other data from experimental studies suggest that the effects of LDL-cholesterol on the arterial wall may be different in the pulmonary and systemic circulation. In rabbits, it has been demonstrated that hypercholesterolemia can increase pulmonary artery relaxation in response to methacholine[@b42]. Another experimental study[@b43] in rats with monocrotaline induced PAH showed that high-fat diet and hypercholesterolemia was associated with better prognosis as compared with standard diet. We have recently shown that low LDL-C levels, together with BMI \< 25 kg/m^2^ and higher pulmonary artery pressure are independent determinants of increased pulmonary artery stiffness and together explain most of the variation in pulmonary artery pulse wave velocity[@b16]. The different role of LDL-C in pulmonary circulation disease compared to the systemic circulation could also have contributed to the negative results of studies with statins in PAH patients[@b44].

Our data suggests a strong linear relationship between LDL-C levels and mortality with a 2- to 5-fold increase in risk of death for every 1 mmol/l decrease in LDL-C. We cannot exclude the possibility that low LDL-C do not have any direct pathophysiologic connection to mortality and is only a consequence of the severity of PAH or malnutrition, which are also associated with poor survival. However, LDL-C levels were associate with all-cause mortality independently from markers of PAH severity -- WHO FC and malnutrition - low BMI. Therefore, our data suggests that the prognostic impact of LDL-C in PAH cannot be fully explained by PAH severity or malnutrition, thereby supporting its potential role as an independent risk marker in PAH. Nevertheless, whether low LDL-C levels represent a modifiable risk marker in PAH or just an epiphenomenon with no direct pathophysiological impact on prognosis still needs to be elaborated.

Our study has several limitations. First, our data cannot provide explanations on the mechanisms by which low LDL-C levels influence survival in PAH patients. However, some plausible hypotheses can be proposed from our data for further studies. Second, as this is an observational study, we cannot establish a cause-and-effect relationship between LDL-C and outcome. Third, we could not ascertain the cause of death and compare the impact of low LDL-C on cardiovascular versus non-cardiovascular mortality or cardiovascular morbidity. Additionally we did not assess specifically dietary patterns of our patients which could have influenced LDL-C level. We also have not given the patients any specific advice on nutrition. This was mainly due to the fact that currently there is no evidence on the proper diet in patients with PAH.

Our study has several important strengths. First, the findings of LDL-C level alterations in the PAH population and their prognostic importance are novel and have not been previously reported. Second, as a control group we used a large representative sample of adults. Third, by using interventional and surgical treatment of CTEPH as a model for reliable, rapid improvement of hemodynamics, we could elaborate the dynamic relationship between LDL-C levels and severity of pulmonary hypertension beyond simple associations at baseline.

In summary, LDL-C levels are low in patients with PAH and are associated with an increased risk of death. Reversal of pulmonary hypertension in CTEPH patients increases low LDL-C levels. Future studies are necessary to gain more insights into the underlying pathophysiology of these findings and their role in the management of PAH.

Methods
=======

Patient population
------------------

Consecutive patients were recruited from the PH Program at the John Paul II Hospital (Krakow, Poland) between February 2009 and January 2015. Adult patients diagnosed with PAH except portopulmonary PAH were eligible for the study. PH was defined as an increase in mPAP ≥25 mmHg at rest as assessed by right heart catheterization[@b3]. PAH was defined as precapillary PH (pulmonary artery wedge pressure ≤15 mmHg) with PVR \> 3 Wood units in the absence of other causes of precapillary PH such as lung diseases, CTEPH or other rare diseases[@b3]. As a control group we chose a representative sample of 2413 Polish residents aged 18--79 years from the NATPOL 2011 Survey, a cross-sectional observational study aimed to assess the prevalence and control of cardiovascular disease risk factors in Poland[@b45]. All-cause mortality was ascertained by data collection from the Department of Nationals' and Foreigners' Affairs and through phone follow-up. The observation period started at the first assessment of the patient in our center and extended until January 2016. We also studied patients with CTEPH from our centre to see whether PH reversal can change LDL-C levels. For this purpose, we formed two subgroups to be compared: CTEPH patients with a significant hemodynamic improvement (rCTEPH) by interventional (BPA), surgical (PEA) or drug treatment. The second subgroup included CTEPH patients not meeting our definition of hemodynamic improvement (nrCTEPH). Significant hemodynamic improvement was defined as a reduction of mPAP by ≥10 mmHg and to \<30 mmHg. This analysis was performed only in patients without changes in statin therapy from 3 months before baseline until follow-up. CTEPH was defined as precapillary PH characterized by mismatched perfusion defects on lung scan and specific diagnostic signs for CTEPH seen by conventional pulmonary cineangiography. The diagnosis of CTEPH could have been established only after at least 3 months of effective anticoagulation[@b3]. The institutional ethics committee (Komisja Bioetyczna - Okregowa Izba Lekarska w Krakowie) approved the registry of patients with PAH and CTEPH in our center and the patients signed the informed consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Clinical assessment and laboratory measurements
-----------------------------------------------

Clinical assessment, laboratory measurements and hemodynamic evaluation were made at the first evaluation of a patient in our center. Clinical assessment included demographic information, patient's history, calculation of BMI, measurement of blood pressure, and N-terminal pro-brain natriuretic peptide (NT-proBNP) level, six minute walk test and assessment of the WHO FC, as well as other tests routinely performed at first evaluation of a PAH patient in our center but not analyzed in the study such as echocardiography. Obesity was defined as BMI ≥30 kg/m^2^, and overweight as BMI ≥25 kg/m^2^ and \<30 kg/m^2^ [@b46]. Hypertension was diagnosed in patients with elevated systolic or diastolic blood pressure (BP) ≥140 or 90 mmHg, respectively or patients having been prescribed a BP-lowering drugs for high BP. On the contrary patients were not classified as hypertensives when they were assuming drugs with BP-lowering effect but prescribed for other reasons than hypertension, e.g. for angina[@b47]. Diabetes was diagnosed based on the plasma glucose criteria of the American Diabetes Association, either the fasting plasma glucose or the 2-h plasma glucose value after a 75-g oral glucose tolerance test[@b48]. Active smoker was defined as having smoked at least for 1 month during the previous 12 months; all others were classified as nonsmokers[@b16]. Peripheral venous blood was drawn after overnight fast in all patients (PAH and CTEPH group) on the day of right heart catheterization. Plasma lipids were measured twice in every patient. In the PAH group measurements were performed at enrollment and three months after enrollment while in the CTEPH group before starting therapy and after at least three months of therapy. Blood chemistry was performed using the Cobas^®^ 6000 analyzer (Roche Diagnostics International Ltd). LDL-C, HDL-C, and TG plasma concentrations were measured directly by using colorimetric technique with PEG-esterase, PEG-oxidase and peroxidase for HDL-C and LDL-C, and with lipase and peroxidase for TG concentrations. AST and ALT assay was performed accordingly to International Federation of Clinical Chemistry and Laboratory Medicine recommendations without pyridoxal phosphate activation. hsCRP was assessed using high sensitive latex assay. Creatinine level was assessed using kinetic colorimetric assay. Hemodynamic evaluation was performed during right heart catheterization using a Swan-Ganz-Catheter. Cardiac output was assessed using the oxygen consumption method. Clinical assessment and laboratory measurements performed in the NATPOL survey control group were described in detail elsewhere[@b45].

Statistical analysis
--------------------

Continuous variables were reported as mean ± standard deviation or as median (interquartile range) and categorical variables as counts and percentages. For the comparison of continuous variables between two groups we used Student's t-test or Mann-Whitney U-test as appropriate and for categorical variables the chi-squared test. The Wilcoxon rank sum test was used for paired comparisons of continuous parameters assessed at baseline and at follow-up. For the comparison of LDL-C levels in three different groups of patients with PAH we used the Kruskal-Wallis test.

To compare patients with controls, the groups were matched for age separately in males and females. Multiple regression analysis using forward stepwise selection was used to assess significant associations between patients' characteristics and LDL-C levels. To exclude possible multicollinearity, we used multicollinearity diagnostic statistics and examined the variance inflation factor.

To assess the relationship between LDL-C and the risk of all-cause mortality, we used Cox proportional hazards regression. To allow for flexible modeling of the association and account for potential non-linearity, we modeled LDL-C using restricted cubic splines.

Models were hierarchically adjusted for major cardiovascular risk factors and markers of severity of PAH: model 1 - unadjusted analysis; model 2: adjusted for age and sex; model 3: adjusted additionally for diabetes, BMI, statin use, hypertension, smoking; model 4 - adjusted additionally for HDL-C, TG; model 5 - adjusted additionally for WHO-FC, etiology of PAH, PAH-specific treatment at the end of observation, NT-proBNP, 6-minute walk distance, RAP, PVR, CI; model 6 - similar to model 5 but PVR was substituted with mPAP. Sample size was calculated for the comparison of LDL-C between the rCTEPH and nrCTEPH at follow-up. We expected that in the rCTEPH group the LDL-C level would increase to the values of control group and that in the nrCTEPH group LDL-C would not change. Consequently, we expected that the difference of mean LDL-C between nrCTEPH group and rCTEPH group at follow-up would be 0.74 mmol/l. For alpha level of 0.05 and beta level of 0.2 the minimal number of patients in each group was 10. When comparing several parameters in the CTEPH group before and after treatment adjustment for multiple comparisons has been done. The significance level was set at alpha level of 0.05. Statistical analysis was performed with Statistica PL software \[StatSoft, Inc. (2010). STATISTICA (data analysis software system), version 9.1. Tulsa, USA [www.statsoft.com](http://www.statsoft.com)\] and MedCalc version 11.6.1.0 (MedCalc Software, Mariakerke, Belgium) and STATA. 14.1 (StataCorp).
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![Low-density lipoprotein cholesterol (LDL-C) levels at baseline and follow-up in the reversed (rCTEPH) and non-reversed chronic thromboembolic pulmonary hypertension (nrCTEPH) patients.\
\*p = 0.6 for the comparison of baseline data between rCTEPH and nrCTEPH group, \*\*p = 0.005 for the comparison of follow-up data between rCTEPH and nrCTEPH group.](srep41650-f2){#f2}

###### Characteristics of patients with pulmonary arterial hypertension.

  PAH group (n = 140)       
  ------------------------- ----------------------------------
  Age (y)                           46 \[28.0--62.0\]
  Sex (male)                             46 (32%)
  PAH etiology              
   IPAH                                  63 (45%)
   CTD-PAH                               17 (12%)
   CHD-PAH                               60 (43%)
  WHO FC (II/III/IV)         19 (13.6%)/99 (70.7%)/22 (15.7%)
  mPAP (mmHg)                      52.0 \[41.0--71.0\]
  RAP (mmHg)                         7.0 \[3.0--9.0\]
  PAWP (mmHg)                       9.0 \[6.0--12.0\]
  Ao mean pressure (mmHg)              92.0 ± 14.2
  CO (l/min)                         3.1 \[2.3--4.3\]
  CI (l/min/m^2^)                   1.75 \[1.4--2.4\]
  PVR (WU)                          15.7 \[9.9--22.5\]
  NT-proBNP (pg/ml)              619.4 \[183.2--2229.0\]
  6MWD (m)                            321.3 ± 133.3

6-MWD -- 6-minute walk distance, Ao -- aorta, CHD-PAH -- pulmonary arterial hypertension associated with congenital heart disease, CI -- cardiac index, CO -- cardiac output, CTD-PAH -- pulmonary arterial hypertension associated with connective tissue disease, IPAH -- idiopathic pulmonary arterial hypertension, mPAP -- mean pulmonary arterial pressure, NT-proBNP -- N-terminal pro-brain natriuretic peptide, PAH -- pulmonary arterial hypertension, PAWP -- pulmonary artery wedge pressure, PVR -- pulmonary vascular resistance, RAP -- right atrial pressure, WHO-FC -- World Health Organization functional class.

###### Cardiovascular risk factors in patients with pulmonary arterial hypertension and age and sex-matched general population.

                                         PAH (n = 140)   Controls (n = 2413)     p-value                               
  ------------------------------------- --------------- --------------------- -------------- -------------- ---------- -----------
  Age (years)                             43.6 ± 17.2        41.6 ± 16.4       44.8 ± 27.1    42.9 ± 24.0      0.49       0.56
  BMI (kg/m^2^)                           23.8 ± 4.16        24.9 ± 5.2         25.9 ± 7.3     27.1 ± 6.7    \<0.001      0.002
  SBP (mmHg)                             109.2 ± 16.9       108.9 ± 16.6       130.1 ± 30.0   136.7 ± 26.9   \<0.0001   \<0.0001
  DBP (mmHg)                              70.3 ± 10.4        70.0 ± 11.3       80.6 ± 13.1    82.4 ± 15.7    \<0.0001   \< 0.0001
  LDL-C (mmol/l)                           2.6 ± 0.8          2.3 ± 0.9         3.2 ± 1.1      3.2 ± 1.2     \<0.0001   \< 0.0001
  LDL-C (mmol/l)\[without statins\]\*      2.6 ± 0.8          2.3 ± 0.8         3.3 ± 1.1      3.3 ± 1.2     \<0.0001   \< 0.0001
  HDL-C (mmol/l)                           1.3 ± 0.4          1.1 ± 0.3         1.4 ± 0.4      1.2 ± 0.5       0.02       0.18
  TG (mmol/l)                              1.3 ± 0.7          1.3 ± 0.8         1.1 ± 0.8      1.6 ± 1.6      0.054       0.19
  Glucose (mmol/l)                         5.4 ± 1.7          5.5 ± 0.9         5.0 ± 1.0      5.3 ± 1.6      0.0003      0.49
  Diabetes                                    10%                3%                5.9%           4.6%         0.17       0.88
  Statin use                                  19%                21%              11.9%          11.2%         0.06       0.07
  Hypertension                                21%                32%               25%           28.2%         0.46       0.69
  Active smoker                              4.9%               7.2%              27.1%          35.6%       \<0.0001    0.0001

BMI -- body mass index, DBP -- diastolic blood pressure, f -- female, m -- male, HDL -- high-density lipoprotein, LDL -- low-density lipoprotein, PAH -- pulmonary arterial hypertension, SBP -- systolic blood pressure, TG -- triglycerides \*the number of patients who had not used statins are as follows: in PAH group: 76 females and 36 males; in control group 1097 females and 1037 males.

###### Univariate linear regression associations between different variables and low-density cholesterol level in patients with pulmonary arterial hypertension (n = 140).

  Variable                          β coefficient (SE)   P value
  -------------------------------- -------------------- ----------
  Age (years)                          0.01 (0.09)         0.88
  Sex (female = 0/male = 1)            −0.18 (0.08)        0.03
  WHO-FC                               −0.2 (0.08)         0.02
  6-MWD                                0.12 (0.09)         0.17
  NT-proBNP                            −0.09 (0.09)        0.35
  AST                                  −0.09 (0.09)        0.32
  ALT                                  −0.09 (0.09)        0.3
  Creatinine                           −0.07 (0.09)        0.38
  PAH etiology                                          
   IPAH (yes = 1/no = 0)               −0.13 (0.09)        0.13
   CTD-PAH (yes = 1/no = 0)            0.12 (0.08)         0.16
   CHD-PAH (yes = 1/no = 0)            0.05 (0.09)         0.56
  Hemodynamic data                                      
   mPAP                                −0.01 (0.09)        0.9
   CI                                  −0.03 (0.09)        0.69
   PVR                                 −0.05 (0.09)        0.59
   RAP                                 −0.18 (0.1)         0.06
  Cardiovascular risk factors                           
   Diabetes (yes = 1/no = 0)           0.04 (0.09)         0.67
   Hypertension (yes = 1/no = 0)       0.04 (0.09)         0.65
   BMI                                  0.1 (0.09)         0.26
   HDL cholesterol                     0.06 (0.09)         0.51
   Triglycerides                        0.4 (0.08)       \<0.0001
  Treatment                                             
   statins (yes = 1/no = 0)            −0.11 (0.08)        0.18
   baseline PAH therapy                0.06 (0.09)         0.45

6-MWD -- 6-minute walk distance, ALT -- alanine aminotransferase, AST -- aspartate aminotransferase, BMI -- body mass index, CHD-PAH -- pulmonary arterial hypertension associated with congenital heart disease, CI -- cardiac index, CTD-PAH -- pulmonary arterial hypertension associated with connective tissue disease, HDL-C -- high density lipoprotein cholesterol, IPAH -- idiopathic pulmonary arterial hypertension, mPAP -- mean pulmonary arterial pressure, NT-proBNP -- N-terminal pro-brain natriuretic peptide, PAH -- pulmonary arterial hypertension, PVR -- pulmonary vascular resistance, RAP -- right atrial pressure, SE -- standard error, WHO-FC -- World Health Organization functional class.

###### Cox regression model for the association between low-density lipoprotein cholesterol and mortality.

             HR (95% CI) per 1 mmol/l     p
  --------- -------------------------- --------
  model 1       0.44 (0.26--0.74)       0.002
  model 2       0.44 (0.26--0.74)       0.002
  model 3       0.44 (0.26--0.74)       0.002
  model 4       0.38 (0.22--0.68)       0.0009
  model 5       0.18 (0.07--0.47)       0.0005
  model 6       0.18 (0.07--0.47)       0.0005

Model 1: unadjusted analysis. Model 2: analysis adjusted for age and sex. Model 3: analysis adjusted for age, sex, diabetes, body mass index (BMI), statin use, hypertension, smoking. Model 4: analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, high density lipoprotein cholesterol (HDL-C), triglycerides. Significant predictor of death were: low-density lipoprotein cholesterol (LDL-C) and HDL-C (0.24; 0.08--0.66). Model 5: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, HDL-C, triglycerides, World Health Organization functional class (WHO-FC), etiology of pulmonary arterial hypertension (PAH), PAH-specific treatment at the end of observation, N-terminal pro-brain natriuretic peptide (NT-proBNP), 6-minute walk distance (6-MWD), right atrial pressure (RAP), pulmonary vascular resistance, cardiac index (CI). Significant predictors of death were: LDL-C and current smoking (6.8; 1.3--35.6), NT-proBNP (1.02; 1.01--1.03), RAP (1.12; 1.02--1.25). Model 6: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, HDL-C, triglycerides, WHO-FC, etiology of PAH, PAH-specific treatment at the end of observation, NT-proBNP, 6-MWD, RAP, mean pulmonary artery pressure, CI. Significant predictors of death were: LDL-C and current smoking (6.8; 1.3--35.6), NT-proBNP (1.02; 1.01--1.03), RAP (1.12; 1.02--1.25).
